CSP Clinical Management: Immunology 5

Question 1

Upadacitinib is best described as which type of agent?

Accepted Answer

Selective JAK1 inhibitor

Answer

Upadacitinib preferentially inhibits JAK1, but it still carries the class boxed warnings for JAK inhibitors.

Question 2

A patient with a history of multiple sclerosis is being considered for psoriatic arthritis therapy. Which class warrants the most caution?

Accepted Answer

TNF inhibitors

Answer

TNF inhibitors have been linked to new or worsening demyelinating disease and should be avoided in MS.

Question 3

Belimumab is used in systemic lupus erythematosus to inhibit which target?

Accepted Answer

B-lymphocyte stimulator (BLyS/BAFF)

Answer

Belimumab binds soluble BLyS, which reduces B-cell survival and differentiation.

Question 4

What is the standard secukinumab dosing for adult plaque psoriasis?

Accepted Answer

300 mg at weeks 0, 1, 2, 3, and 4, then every 4 weeks

Answer

Secukinumab is loaded weekly for 5 doses and then given every 4 weeks as maintenance.

Question 5

A patient is HBsAg-negative and anti-HBc-positive, and is about to start a TNF inhibitor. What is the best approach?

Accepted Answer

Monitor HBV DNA and ALT or give antiviral prophylaxis per hepatology guidance

Answer

A resolved HBV infection can reactivate under immunosuppression, so monitoring or prophylaxis is recommended.

CSP - Certified Specialty Pharmacist Practice Test